These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30641166)

  • 21. Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study.
    Guja C; Frías JP; Somogyi A; Jabbour S; Wang H; Hardy E; Rosenstock J
    Diabetes Obes Metab; 2018 Jul; 20(7):1602-1614. PubMed ID: 29473704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dosing of insulin glargine in the treatment of type 2 diabetes.
    Barnett A
    Clin Ther; 2007 Jun; 29(6):987-99. PubMed ID: 17692716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HbA1c target achievement in the elderly: results of the Titration and Optimization trial for initiation of insulin glargine 100 U/mL in patients with type 2 diabetes poorly controlled on oral antidiabetic drugs.
    Fritsche A; Anderten H; Pfohl M; Pscherer S; Borck A; Pegelow K; Bramlage P; Seufert J
    BMJ Open Diabetes Res Care; 2019; 7(1):e000668. PubMed ID: 31423316
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diabetes duration and the efficacy and safety of insulin glargine versus comparator treatment in patients with type 2 diabetes mellitus.
    Garg SK; Aurand LA; Rimler MS; Dailey GE
    Endocr Pract; 2014 Feb; 20(2):120-8. PubMed ID: 24013981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fasting Glucose of 6.1 mmol/L as a Possible Optimal Target for Type 2 Diabetic Patients with Insulin Glargine: A Randomized Clinical Trial.
    Yuan L; Li F; Zhou Y; Sun R; Gao G; Zhang Q; Tang Y; Dai L; Wu J; Ma J
    J Diabetes Res; 2021; 2021():5524313. PubMed ID: 34337072
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes.
    Yale JF; Aroda VR; Charbonnel B; Sinclair AJ; Trescoli C; Cahn A; Bigot G; Merino-Trigo A; Brulle-Wohlhueter C; Bolli GB; Ritzel R
    Diabetes Metab; 2020 Apr; 46(2):110-118. PubMed ID: 30366067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of clinically relevant hypoglycaemia in patients with type 2 diabetes self-titrating insulin glargine U-100.
    Hollander PA; Kiljanski J; Spaepen E; Harris CJ
    Diabetes Obes Metab; 2019 Nov; 21(11):2413-2421. PubMed ID: 31264764
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape).
    Vora J; Cohen N; Evans M; Hockey A; Speight J; Whately-Smith C
    Diabetes Obes Metab; 2015 Dec; 17(12):1133-41. PubMed ID: 26085028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).
    Bolli GB; Riddle MC; Bergenstal RM; Ziemen M; Sestakauskas K; Goyeau H; Home PD;
    Diabetes Obes Metab; 2015 Apr; 17(4):386-94. PubMed ID: 25641260
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Baseline HbA1c predicts attainment of 7.0% HbA1c target with structured titration of insulin glargine in type 2 diabetes: a patient-level analysis of 12 studies.
    Riddle MC; Vlajnic A; Zhou R; Rosenstock J
    Diabetes Obes Metab; 2013 Sep; 15(9):819-25. PubMed ID: 23489438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis).
    Roussel R; d'Emden MC; Fisher M; Ampudia-Blasco FJ; Stella P; Bizet F; Cali AMG; Wysham CH
    Diabetes Obes Metab; 2018 Feb; 20(2):448-452. PubMed ID: 28736942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insulin Glargine U100 Utilization in Patients with Type 2 Diabetes in an Italian Real-World Setting: A Retrospective Study.
    Esposti LD; Perrone V; Saragoni S; Blini V; Buda S; D'avella R; Gasperini G; Lena F; Fanelli F; Gazzi L; Giorgino F
    J Diabetes Res; 2019; 2019():3174654. PubMed ID: 31976334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Traveling Across Time Zones With Type 1 Diabetes: A Pilot Study Comparing Insulin Degludec With Insulin Glargine U100.
    Bevier WC; Castorino KN; Axelrod C; Haroush G; Farfan CC; Shelton N; Nelson K; Spink LA; Liu H; Kerr D
    Diabetes Care; 2022 Jan; 45(1):67-73. PubMed ID: 34716211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Telephone-Delivered Interventions on Glycemic Control in Type 2 Diabetes Treated with Glargine Insulin.
    Bellido V; Bellido D; Tejera C; Carral F; Goicolea I; Soto A; García Almeida JM; Morales C; López de la Torre M
    Telemed J E Health; 2019 Jun; 25(6):471-476. PubMed ID: 30036160
    [No Abstract]   [Full Text] [Related]  

  • 35. Titration and optimization trial for the initiation of insulin glargine 100 U/mL in patients with inadequately controlled type 2 diabetes on oral antidiabetic drugs.
    Seufert J; Fritsche A; Pscherer S; Anderten H; Borck A; Pegelow K; Bramlage P; Pfohl M
    Diabetes Obes Metab; 2019 Feb; 21(2):439-443. PubMed ID: 30226296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparable efficacy with similarly low risk of hypoglycaemia in patient- vs physician-managed basal insulin initiation and titration in insulin-naïve type 2 diabetic subjects: The Italian Titration Approach Study.
    Bonadonna RC; Giaccari A; Buzzetti R; Perseghin G; Cucinotta D; Avogaro A; Aimaretti G; Larosa M; Fanelli CG; Bolli GB
    Diabetes Metab Res Rev; 2020 Sep; 36(6):e3304. PubMed ID: 32118347
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TITRATION: A Randomized Study to Assess 2 Treatment Algorithms with New Insulin Glargine 300 units/mL.
    Yale JF; Berard L; Groleau M; Javadi P; Stewart J; Harris SB
    Can J Diabetes; 2017 Oct; 41(5):478-484. PubMed ID: 28803820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P; Cooper J; Bregnhøj J; Pedersen CB
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100.
    Lingvay I; Buse JB; Franek E; Hansen MV; Koefoed MM; Mathieu C; Pettus J; Stachlewska K; Rosenstock J
    Diabetes Care; 2021 Jul; 44(7):1595-1603. PubMed ID: 33875484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study.
    Blonde L; Merilainen M; Karwe V; Raskin P;
    Diabetes Obes Metab; 2009 Jun; 11(6):623-31. PubMed ID: 19515182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.